Silicon Valley's burning bank The bank's failure would be the biggest since Washington Mutual. Axios · Mar 10, 2023
Silicon Valley Bank fails in largest bank collapse since 2008 crisis US regulators seize SVB’s assets after a run on the bank, as global institutions monitor situation closely The Guardian - UK · Mar 10, 2023
VCs describe a big mess as Silicon Valley Bank’s troubles spark panic Founders are pulling cash from Silicon Valley Bank as fear of a bank run has spread. Fortune · Mar 10, 2023
What happened to Silicon Valley Bank? Behind the remarkable reversal of fortune for the startup world's bank of choice. Axios · Mar 10, 2023
French, German banks take a pasting on solvency fears at US lender The value of shares in France's major banks sank on Friday after trouble at a regional US lender sparked a Wall Street rout on the sector in the United States. Deutsche Bank shares were down nearly 10 percent at the opening in Frankfurt. Radio France Internationale · Mar 10, 2023
Bill Ackman thinks the government should consider SVB bailout The founder of Pershing Square Capital Management said the collapse of Silicon Valley Bank "could destroy a long-term driver of the economy." Fortune · Mar 10, 2023
US adds 311,000 jobs in February; UK economy returns to growth; regulators take over Silicon Valley Bank – as it happened UK economy has proved ‘more resilient than many expected’ says chancellor Jeremy Hunt, while problems at Silicon Valley Bank knock FTSE 100 down 2% The Guardian - UK · Mar 10, 2023
VCs and startup founders are freaking out about Silicon Valley Bank Startup founders are pulling cash from Silicon Valley Bank, even as some VCs say the panic is overblown and fueling the fire. Fortune · Mar 10, 2023
Silicon Valley Bank spooks Silicon Valley Several top VC firms, including Coatue and Founders Fund, today suggesting pulling money out of SVB. Axios · Mar 9, 2023
Silicon Valley Bank creates UK subsidiary in boost for London’s tech sector The firm said the move reflects the strong growth of tech businesses in the UK Evening Standard · Sep 22, 2022
Municipal Corporation Faridabad and Wakf Board officials arrested caught taking Rs 80,000 bribe CHANDIGARH: Haryana State Vigilance Bureau has arrested two officials posted in Municipal Corporation Faridabad and Waqf Board, Bhiwani red-handed while accepting bribe worth Rs 50,000 and Rs 30,000 respectively. Both have been booked under the Prevention of Corruption Act. The Times of India · Aug 31, 2022
Haryana: Case against 3 over university BAMS paper leak KURUKSHETRA: In connection with the bachelor of ayurvedic medicine and surgery (BAMS) course 'paper leak case' of Shri Krishna Ayush University (SKAU), Kurukshetra of January 2020, after over two and a half years, the Haryana State Vigilance Bureau (SVB) booked three persons including a clerk, a computer operator, former employees… The Times of India · Jul 30, 2022
This Analyst Thinks Blueprint Medicines' Non-Dilutive Funding 'Deflates M&A Speculation' Today Blueprint Medicines Corp (NASDAQ:BPMC) announced strategic financing agreements with Sixth Street and Royalty Pharma Plc (NASDAQ:RPRX) for up to $1.25 billion, including $575 million upfront upon deal closure. SVB Securities thinks the terms of the deals are fairly valued on the Sixth Street portion and favorable for Blueprint Medicines on the Royalty Pharma portion. "In addition,… Benzinga · Jun 30, 2022
This Analyst Says US Government Buying More COVID-19 Vaccines At Higher Prices Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced a new COVID-19 vaccine supply agreement with the U.S. government. SVB Leerink says that the new contract implies the price per Comirnaty dose is ~$30.50. Comirnaty U.S. pricing per dose has increased from $19.50 (2020 contracts), to $24 (+23%; 2021 contract), and now to ~$30.50 (+27%). The analysts… Benzinga · Jun 30, 2022
Benzinga · Jun 29, 2022 What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder Axsome Therapeutics Inc (NASDAQ: AXSM) held an investor event to review its strategy with Sunosi, which is indicated for excessive daytime sleepiness (EDS) in narcolepsy and obstructive sleep apnea (OSA). SVB Leerink says its view on Sunosi has not changed.
Benzinga · Jun 27, 2022 Analysts Believe Madrigal's Resmetirom Shows Impressive Overall Profile In Liver Fibrosis Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) presented multiple resmetirom abstracts at the European Association for the Study of the Liver's International Liver Congress. The data included new details on changes in FibroScan controlled attenuation parameter and liver stiffness measurement along with magnetic resonance elastography, which serves as critical non-invasive measures of liver stiffness and fibrosis. …
Benzinga · Jun 21, 2022 SVB Leerink's Pro-forma Analysis Of Speculated Merck/Seagen Deal - What Investors Need To Know SVB Securities conducted a pro-forma analysis of the financial impact to Merck & Co Inc (NYSE: MRK) from a potential acquisition of Seagen Inc (NASDAQ: SGEN).
Benzinga · Jun 13, 2022 Jefferies Maintains Buy Rating for SVB Finl Gr: Here's What You Need To Know Jefferies has decided to maintain its Buy rating of SVB Finl Gr (NASDAQ:SIVB) and lower its price target from $692.00 to $534.00. Shares of SVB Finl Gr are trading down 7.14% over the last 24 hours, at $411.27 per share. A move to $534.00 would account for a 29.84% increase…
Benzinga · Jun 6, 2022 SVB Leerink Sees Over 600% Upside For This Penny Biotech Stock SVB Leerink initiated Selecta Biosciences Inc (NASDAQ:SELB) coverage with an Outperform rating and a price target of $7. The analysts view ImmTOR's approach to mitigate ADAs as de-risked by early clinical data from SEL-212 and believe that the ability to tame the immune response bodes well for ImmTOR's clinical potential in combination with…
Benzinga · Jun 6, 2022 Regulatory Update On Intercept Pharma's Obeticholic Acid For NASH Delayed Again Intercept Pharmaceuticals Inc's (NASDAQ:ICPT) pre-submission meeting to discuss the marketing application for obeticholic acid (OCA) in NASH has been moved to July (vs. June scheduling). The update follows a recent request from the FDA that topline data from the REGENERATE reanalysis be provided to the agency for review before the meeting. SVB Leerink…
Benzinga · May 24, 2022 SVB Sees De-Risked Opportunity For This Newly Listed Norovirus Vaccine SVB Leerink is initiating coverage of HilleVax Inc (NASDAQ:HLVX) shares with an Outperform rating and a $30 price target. The analyst believes the company’s potentially first-in-class infant norovirus vaccine HIL214 represents a uniquely de-risked opportunity. It estimates $625 million in risk-adjusted infant HIL214 sales in 2030E ($1 billion unadjusted). The outlook is supported by…
Benzinga · May 24, 2022 SVB Sees Strategic Value In This Stock As M&A Target In Autoimmune Space SVB Securities initiated coverage on Argenx SE (NASDAQ:ARGX) with an Outperform rating and a $404 price target. Argenx's Vyvgart (efgartigimod) is a neonatal Fc-Receptor (FcRn) antagonist that selectively reduces IgG levels and has the potential to address numerous IgG-mediated autoimmune diseases. According to the analyst, Argenx has demonstrated strong early launch execution for Vyvgart…
Benzinga · May 13, 2022 ACHV: First Quarter 2022 Results By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT
Benzinga · May 2, 2022 Here's Why This Analyst Is On Sidelines Despite European Approval Of Myovant's Relugolix For Prostate Cancer Myovant Sciences Ltd (NYSE:MYOV) received European approval for Orgovyx (relugolix, 120 mg) for advanced hormone-sensitive prostate cancer, and SVB Securities think Orgovyx could be a ~$1 billion product in advanced prostate cancer long term. But the surprise Myfembree setback in endometriosis has sparked uncertainty and new investor questions for Myovant's 2nd program. Hence, SVB remains on the…
Benzinga · Mar 11, 2022 ACHV: 2021 Results: ORCA-3 Underway, ORCA-V1 Soon to Start By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT